RxDoctor Payments Data

Alexander Reichard, MD

Adult Reconstructive Orthopaedic Surgery · Spokane, WANPI 1174781421

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $40,950 of the $49,266 with a category attached, or 83.1%. Medical Device Business Services, Inc. accounts for 91.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $27,311 and has fallen 96.9% since, to $858 in 2025.

$49,266in general payments, 2019–2025

Across 72 payments — averaging $684.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$45K
  • Johnson & Johnson$4K
  • Davol Inc.$114
  • Heron Therapeutics, Inc.$89

What the payments were for

  • Consulting fees$40,95083%
  • Travel & lodging$5,62911%
  • Food & beverage$2,6875%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few adult reconstructive orthopaedic surgery providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$305,511
Medicare patients
338
Services billed
2,857

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban29$14,164
Celecoxib91$2,167
Oxycodone Hcl276$2,002
Amoxicillin428$954
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen81$758
Cephalexin204$541
Ondansetron Hcl111$375
Hydroxyzine Pamoate26$193
Clindamycin Hcl69$191
Meloxicam32$162
Hydromorphone Hcl13$118
Pregabalin34$115
Tramadol Hcl22$99
Tamsulosin Hcl33$65

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$4,148$14,16429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult reconstructive orthopaedic surgery providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other adult reconstructive orthopaedic surgery in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →